BLUESTAR ADISSEO COMPANY |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.04 CNY | -0.33% |
|
-0.22% | +13.00% |
| Mar. 29 | Bluestar Adisseo's 2023 Profit Plummets 96% | MT |
| Mar. 28 | Bluestar Adisseo Company Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 15.17B 2.1B | Sales 2025 * | 17.21B 2.38B | Capitalization | 24.32B 3.36B |
|---|---|---|---|---|---|
| Net income 2024 * | 865M 119M | Net income 2025 * | 1.14B 158M | EV / Sales 2024 * | 1.68 x |
| Net Debt 2024 * | 1.2B 166M | Net Debt 2025 * | 1.14B 157M | EV / Sales 2025 * | 1.48 x |
| P/E ratio 2024 * |
28
x | P/E ratio 2025 * |
21.3
x | Employees | 2,734 |
| Yield 2024 * |
0.92% | Yield 2025 * |
1.47% | Free-Float | 13.47% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.89% | ||
| 1 week | +0.11% | ||
| Current month | +5.10% | ||
| 1 month | +6.33% | ||
| 3 months | +12.39% | ||
| 6 months | +11.02% | ||
| Current year | +13.38% |
1 week
8.94
9.45
1 month
8.209.45
Current year
6.459.45
1 year
6.459.45
3 years
6.4513.85
5 years
6.4516.80
10 years
6.4521.36
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 70 | 15-10-22 | |
Deng Jie Gu
PRN | Corporate Officer/Principal | 60 | 15-10-22 |
Yun Cai
SEC | Corporate Secretary | 50 | 15-10-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 78 | 09-12-31 | |
| Director/Board Member | 66 | 21-09-22 | |
| Chief Executive Officer | 70 | 15-10-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 31 M€ | +1.27% | - | |
| 0.00% | 34 M€ | +1.25% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 9.04 | -0.33% | 5 303 835 |
| 24-04-17 | 9.07 | +0.89% | 7,231,607 |
| 24-04-16 | 8.99 | -2.49% | 9,762,595 |
| 24-04-15 | 9.22 | +0.33% | 6,639,645 |
| 24-04-12 | 9.19 | +0.33% | 4,052,151 |
End-of-day quote Shanghai S.E., April 16, 2024
More quotes
Bluestar Adisseo Co is a China-based company principally engaged in the research, design, production and distribution of additives for animal nutrition. The Companyâs products include functional products, special products and others. Its functional products include methionine, vitamins, ammonia sulfates, as well as sodium sulfates, among others. Its special products include enzyme preparations, organic selenium additives and others. The Company also provides carbon disulfide, sulfuric acid and preparation services. The Company operates its business in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
9.07
CNY
Average target price
9.81
CNY
Spread / Average Target
+8.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.38% | 3.36B | |
| -23.02% | 69.43B | |
| -10.00% | 6.61B | |
| +3.06% | 3.28B | |
| +6.76% | 1.51B | |
| -17.73% | 1.33B | |
| -5.47% | 1.23B | |
| -28.33% | 1.2B | |
| -16.78% | 1.09B | |
| -2.87% | 1.02B |
- Stock Market
- Equities
- 600299 Stock
